The trademark application AREVERSIN was filed by Pharmaselect International Beteiligungs GmbH, a corporation established under the laws of the Republic of Austria (the "Applicant"). The application was published for oppositions on September 9, 2024, and still open for oppositions.
The application was filed in German (English was selected as the second language).